Professional Seasonal Analysis for Trading

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)

Seasonality Analysis

Stocks 6 Years Analyzed

NewAmsterdam Pharma Company N.V. - Ordinary Shares Annual Seasonality Statistics

30.42%
Avg Annual Return
56.1%
Avg Monthly Win Rate
7/12
Positive Months
6
Years Analyzed

NewAmsterdam Pharma Company N.V. - Ordinary Shares Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January BEST 13.00%
40%
Weak
February 3.35%
67%
Strong
March -0.36%
67%
Weak
April 2.63%
100%
Strong
May WORST -6.55%
0%
Very Weak
June -3.17%
60%
Weak
July -0.45%
40%
Weak
August -0.06%
40%
Weak
September 1.72%
60%
Moderate
October 7.10%
80%
Very Strong
November 1.72%
60%
Moderate
December 11.49%
60%
Moderate

NewAmsterdam Pharma Company N.V. - Ordinary Shares 2026 vs Historical Pattern

Current Position
68.94
Historical Avg Position
37.65
Deviation
+31.29
Performance
Significantly Above Average

NewAmsterdam Pharma Company N.V. - Ordinary Shares Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for NAMS with overlay patterns, custom date ranges, and more.

Create Free Account

NewAmsterdam Pharma Company N.V. - Ordinary Shares Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

NewAmsterdam Pharma Company N.V. - Ordinary Shares Seasonal Historical Performance

Historical Performance

See historical average returns for NAMS across multiple timeframes.

Create Free Account

About NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS) Seasonality

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS) has been analyzed using 6 years of historical data to identify seasonal patterns. Classified under Stocks, NewAmsterdam Pharma Company N.V. - Ordinary Shares shows distinct seasonal tendencies based on historical data.

The strongest month for NewAmsterdam Pharma Company N.V. - Ordinary Shares is historically January, with an average return of 13.00% and a win rate of 40%. Conversely, May tends to be the weakest month, averaging -6.55% return.

Looking at the full calendar year, NewAmsterdam Pharma Company N.V. - Ordinary Shares has an average annual return of 30.42% with an overall monthly win rate of 56.1%. Out of 12 months, 7 typically show positive average returns.

The seasonal pattern for NewAmsterdam Pharma Company N.V. - Ordinary Shares has a consistency score of 59.5 (Fair), based on 6 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

NewAmsterdam Pharma Company N.V. - Ordinary Shares Seasonality FAQ

What is the best month to buy NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)?

Historically, January has been the best month for NewAmsterdam Pharma Company N.V. - Ordinary Shares, with an average return of 13.00% and a win rate of 40%. However, past performance does not guarantee future results.

What is the worst month for NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)?

Based on historical data, May has been the weakest month for NewAmsterdam Pharma Company N.V. - Ordinary Shares, with an average return of -6.55%. This is a historical observation and does not guarantee future results.

How reliable is NAMS seasonality data?

The seasonality analysis for NewAmsterdam Pharma Company N.V. - Ordinary Shares is based on 6 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use NewAmsterdam Pharma Company N.V. - Ordinary Shares seasonality in my trading?

Use NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.